Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025

About this update from Crinetics Pharmaceuticals, Inc.

SAN DIEGO , June 16, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that it will host an in-person and virtual R&D Day in New York on Thursday, June 26, 2025 , from 9:00 AM to 12:00 PM ET . The event will provide an update including data on Crinetics' early-stage pipeline assets, next steps, and portfolio strategy to drive long-term value. Key topics will include: NETs and beyond – NDC platform with CRN09682 Graves’ disease and thyroid eye disease (TED) - TSH antagonist Autosomal polycystic kidney disease (ADPKD) - SST3 agonist A live question-and-answer session will follow the formal presentations. To register, click here . About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. Investors: Gayathri Diwakar Head of Investor Relations [email protected] (858) 345-6340 Media: Natalie Badillo Head of Corporate Communications [email protected] (858) 345-6075 Source: Crinetics Pharmaceuticals, Inc.

View stock analysis, news, and events for Crinetics Pharmaceuticals, Inc.